AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Medicus Pharma Ltd. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01JPD08P6
2.50▼ 0.12 (-4.58%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.62
Day's Range
2.50 – 2.61
52-Week Range
0.08 – 4.69
Volume
81.9K
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
16
Exchange
XNAS
Listed
2023-11-22
Share count as of August 10, 2026

Medicus Pharma Ltd. Common Stock (MDCX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Medicus Pharma Ltd. Common Stock (MDCX)
What is Medicus Pharma Ltd. Common Stock's Market Cap?
Medicus Pharma Ltd. Common Stock's Market Cap is $158.0M, based on as-reported figures from SEC (XBRL) filings.
What is Medicus Pharma Ltd. Common Stock's Enterprise Value?
Medicus Pharma Ltd. Common Stock's Enterprise Value is $142.8M, based on as-reported figures from SEC (XBRL) filings.
What is Medicus Pharma Ltd. Common Stock's Net Income (TTM)?
Medicus Pharma Ltd. Common Stock's Net Income (TTM) is -$56.7M, based on as-reported figures from SEC (XBRL) filings.
What is Medicus Pharma Ltd. Common Stock's Diluted EPS (TTM)?
Medicus Pharma Ltd. Common Stock's Diluted EPS (TTM) is -0.90, based on as-reported figures from SEC (XBRL) filings.
What is Medicus Pharma Ltd. Common Stock's Net Debt?
Medicus Pharma Ltd. Common Stock's Net Debt is -$15.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MDCXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024
Operating expenses:
General and administrative
Research and development
Total operating expenses
Loss from operations
Other income (expense)
Finance income——
Interest (expense)——
Loss on SEPA (as defined below) settlements
Change in fair value of debentures—
Total other income (expense)
Net loss for the period
Comprehensive loss for the period attributable to common shareholders———
Net loss attributable to
Common shareholders of the Company
Non-controlling interests
Comprehensive loss attributable to
Net loss per share attributable to common shareholders - basic
Net loss per share attributable to common shareholders - diluted